Roche Holding AG ( [RHHBY](/stock/RHHBY/summary) , [Financial](/financials/RHHBY) ) sits atop the list of pharmaceutical companies that are getting the most out of research and development spending. That’s an important consideration for investors given new products with blockbuster potential are the lifeblood of the industry. Using data from a recent Evaluate Advantage consulting group report, Fierce Pharma zeroed in on the recent approvals for 11 of the world’s leading drugmakers by sales.
Read the source article at Value Investing
2021-08-23 23:48:00
